FDA official logo
GSRS logoPFDA official logo

VADASTUXIMAB TALIRINE

UNII:T13V17U431
Formula:
Preferred Substance Name:VADASTUXIMAB TALIRINE
GSRS Full Record:
T13V17U431
i

  • 1436390-64-5
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 3) (HUMAN-MUS MUSCULUS MONOCLONAL H2H12EC HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL H2H12EC LIGHT CHAIN, DIMER, BIS(THIOETHER) WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)-L-VALYL-N-(4-((11AS)-8-(3-(((11AS)-5,11A-DIHYDRO-7-METHOXY-2-(4-METHOXYPHENYL)-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-8-YL)OXY)PROPOXY)-5,11A-DIHYDRO-7-METHOXY-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-2-YL)PHENYL)-L-ALANINAMIDE
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD33 (SIALIC ACID BINDING LG-LIKE LECTIN 3, SIGLEC3, SIGLEC-3, GP67, P67)), CHIMERIC MONOCLONAL ANTIBODY CONJUGATED TO THE PYRROLOBENZODIAZEPINE (PDB) DIMER SGD-1882 GAMMA1 HEAVY CHAIN (1-447) (MUS MUSCULUS VH (IGHV1-85*01 -(IGHD)-IGHJ4*01) (8.8.10) (1 -117) -HOMO SAPIENS IGHG1*01, G1M17,1 (CH1 (118-215), HINGE (216-230), CH2 S3>C (239) (231-340), CH3 (341-445), CHS (446-447)) (118-447)), (220-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (MUS MUSCULUS V-KAPPA (IGKV14-111*01 -HOMO SAPIENS IGKJ4*01) (6.3.9) (1'-107') -HOMO SAPIENS IGKC*01, KM3 (108'-214')) DIMER (226-226'':229-229'')-BISDISULFIDE CONJUGATED, ON TWO SITE-SPECIFIC DRUG ATTACHMENT ENGINEERED CYSTEINES (C239, C239''), TO A MAXIMUM OF 2 PYRROLOBENZODIAZEPINE (PDB) DIMERS SGD-1882, EACH VIA A CLEAVABLE (VALINE-ALANINE DIPEPTIDE AS CATHEPSINE B CLEAVAGE SITE) MALEIMIDOCAPROYL TYPE LINKER
  • SGNCD33A
  • SGN-CD33A
  • VADASTUXIMAB TALIRINE [INN]
  • VADASTUXIMAB TALIRINE [USAN]
  • VADASTUXIMAB TALIRINE [WHO-DD]




UNII - T13V17U431 | UNII Search Service